

REMARKS

The present amendment cancels claims 1-47 and 60-62 without prejudice to Applicants' right to prosecute which are directed to other patentably distinct groups disclosed and claimed in the present application. With entry of the present amendment claims 48-52 and new claims 63-75 will be pending. The specification has been amended to include information relating to the co-pending parent application, to cancel pages i-iii comprising a Table of Contents, and to incorporate the American Type Culture Collection Accession numbers. Further, claims 48-52 have been amended to remove the multiple dependency. New claims 63-75 have been added to encompass the subject matter of the multiple dependency. No new matter is believed to be added by the above amendments.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested. If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 206-467-9600.

Respectfully submitted,

Dated: 1 November 2001

By: Brian W. Poor  
Brian W. Poor  
Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (206) 467-9600  
Fax: (415) 576-0300  
BWP:ww  
SE 5010162 v1

TOWNSEND and CREW LLP

## APPENDIX

### VERSION WITH MARKINGS TO SHOW CHANGES MADE

#### IN THE SPECIFICATION:

| <u>Microorganisms</u>                  | <u>Accession Number</u> |
|--|-------------------------|
| CAT-RFT-pPROTA in E. coli INV $\alpha$ | [—] <u>207225</u>       |
| FL-RFT-pcDNA3 in E. coli DH5 $\alpha$  | [—] <u>207224</u>       |

#### IN THE CLAIMS:

1           48. (Amended) A method for the preparative synthesis of a molecule  
2 comprising Fuc $\alpha$ 1 $\rightarrow$ 2Gal $\beta$ 1 $\rightarrow$ 3GalNAc, said method comprising contacting [the]an isolated  
3 or purified [rat]  $\alpha$ 1 $\rightarrow$ 2fucosyltransferase [of Claim 1, 2, 3, 4, 5, 6, or 8] comprising an amino  
4 acid sequence as depicted in Figure 5 (SEQ ID NO: 8) with GDP-fucose and a molecule  
5 having a terminal Gal $\beta$ 1 $\rightarrow$ 3GalNAc moiety and recovering [a]the molecule comprising  
6 Fuc $\alpha$ 1 $\rightarrow$ 2Gal $\beta$ 1 $\rightarrow$ 3GalNAc.

1           49. (Amended) A method for the preparative synthesis of a glycolipid,  
2 glycoprotein, glycolipoprotein or free oligosaccharide comprising Fuc $\alpha$ 1 $\rightarrow$ 2Gal $\beta$ 1 $\rightarrow$ 3GalNAc,  
3 said method comprising contacting [the]an isolated or purified [rat  $\alpha$ 1 $\rightarrow$ 2fucosyltransferase of  
4 claim 1, 2, 3, 4, 5, 6 or 8]protein comprising an amino acid sequence as depicted in Figure 5  
5 (SEQ ID NO: 8) with GDP-fucose and a glycolipid, glycoprotein, glycolipoprotein or free  
6 oligosaccharaide having a terminal Gal $\beta$ 1 $\rightarrow$ 3GalNAc moiety and recovering [a]the glycolipid,  
7 glycoprotein, glycolipoprotein or free oligosaccharaide comprising  
8 Fuc $\alpha$ 1 $\rightarrow$ 2Gal $\beta$ 1 $\rightarrow$ 3GalNAc.

1           50. (Amended) The method according to Claim 49 wherein the [rat]  
2  $\alpha$ 1 $\rightarrow$ 2fucosyltransferase is contacted with an oligosaccharide comprising a terminal  
3 Gal $\beta$ 1 $\rightarrow$ 3GalNAc moiety.

1                   51. (Amended) A method for the preparative synthesis of fucosyl-GM<sub>1</sub>  
2 comprising contacting [the]an isolated or purified [rat]  $\alpha 1 \rightarrow 2$  fucosyltransferase [of Claim 1, 2,  
3 3, 4, 5, 6 or 8]comprising an amino acid sequence as depicted in Figure 5 (SEQ ID NO: 8) with  
4 GDP-fucose and the ganglioside GM<sub>1</sub> and recovering fucosyl-GM<sub>1</sub>.

1                   52. (Amended) A method for the preparative synthesis of a molecule  
2 comprising Fuca1  $\rightarrow$  2Gal $\beta$ 1  $\rightarrow$  3GalNAc, said method comprising contacting [the isolated or  
3 purified rat]a recombinant  $\alpha 1 \rightarrow 2$  fucosyltransferase [of Claim 33, 36, 39, or 42] or [the]a  
4 cellular fraction [of Claim 34, 37, 40, or 43]of a recombinant cell containing a vector having a  
5 nucleotide sequence that encodes and expresses an amino acid sequence as depicted in Figure 5  
6 (SEQ ID NO: 8) and having  $\alpha 1 \rightarrow 2$  fucosyltransferase activity, with GDP-fucose and a  
7 molecule having a terminal Gal $\beta$ 1  $\rightarrow$  3GalNAc moiety and recovering a molecule comprising  
8 Fuca1  $\rightarrow$  2Gal $\beta$ 1  $\rightarrow$  3GalNAc.

1                   53. (Amended) A method for the preparative synthesis of a glycolipid,  
2 glycoprotein, glycolipoprotein or free oligosaccharide comprising Fuca1  $\rightarrow$  2Gal $\beta$ 1  $\rightarrow$  3GalNAc,  
3 said method comprising contacting [the]an isolated or purified recombinant produced rat  
4  $\alpha 1 \rightarrow 2$  fucosyltransferase [of Claim 33, 36, 39, or 42] or [the]a cellular fraction [of Claim 34,  
5 37, 40, or 43]of a recombinant cell containing a vector having a nucleotide sequence as  
6 depicted as SEQ ID NO: 7 and having  $\alpha 1 \rightarrow 2$  fucosyltransferase activity, with GDP-fucose and  
7 a glycolipid, glycoprotein, glycolipoprotein or oligosaccharide having a terminal  
8 Gal $\beta$ 1  $\rightarrow$  3GalNAc moiety and recovering a glycolipid, glycoprotein, glycolipoprotein or free  
9 oligosaccharide comprising Fuca1  $\rightarrow$  2Gal $\beta$ 1  $\rightarrow$  3GalNAc.

1004083-10401  
TOTAL SHEET